HEBERSaVax: Cuban Biotechnology Innovation Facing the Global Challenge of Cancer

Singapore, June 10th,2 026

 

The results of the therapeutic vaccine candidate HEBERSaVax are encouraging. This unique product, developed by the scientific talent of #Cuba, is the first of its kind in the world.

What makes HEBERSaVax such a promising project?

 

Dual mechanism of action: It acts as an active immunotherapy, generating specific antibodies to cut off the nutrients and oxygen the tumor needs to grow, while simultaneously reactivating the body's defenses.

 

Safety and tolerability: Phase II clinical trials demonstrate that it is a safe therapy, administered subcutaneously, with minimal adverse effects, allowing it to be combined with conventional treatments without increasing toxicity.

 

Clinical evidence: Patients with advanced stages of solid tumors (colorectal, ovarian, renal, and hepatocellular carcinoma) have shown complete clinical responses and significant improvements in their quality of life.

 

Despite the severe financial and resource limitations the country faces due to the inhumane blockade imposed by the #USA, the Cuban scientific community does not renounce its humanist vocation: to investigate, innovate and defend the fundamental right to health and life.

 

(EmbaCuba Singapore)